First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial

Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Jean Philippe Spano, Herve Lena, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel

Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Journal Issue: August
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Jean Philippe Spano, Herve Lena, Philippe Fraisse, Henri Janicot, Clarisse Audigier-Valette, Alexandra Langlais, Franck Morin, Alain Makinson, Jacques Cadranel. First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009



Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial
Source: Eur Respir J 2002; 20: Suppl. 38, 187s
Year: 2002

Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002

Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
Source: Eur Respir J 2003; 22: Suppl. 45, 28s
Year: 2003

Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015

A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 781s
Year: 2006

Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Source: Eur Respir J 2015; 46: 219-229
Year: 2015



Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 241s
Year: 2007

Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001

A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016


Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Randomized phase III-trial of platinum- vs. non-platinum-based chemotherapy in stage IV non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013